Informações:
Falhas:
ID
16897
Descrição
Clozapine and Olanzapine Treatment of Aggression; ODM derived from: https://clinicaltrials.gov/show/NCT01123408
Link
https://clinicaltrials.gov/show/NCT01123408
Palavras-chave
Versões (1)
- 13/08/2016 13/08/2016 -
Transferido a
13 de agosto de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Schizophrenia NCT01123408
Eligibility Schizophrenia NCT01123408
- StudyEvent: Eligibility
Similar models
Eligibility Schizophrenia NCT01123408
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Age
Item
age: 18 to 60 years.
boolean
C0001779 (UMLS CUI [1])
Schizophrenia or schizoaffective disorder
Item
diagnosis of schizophrenia or schizoaffective disorder.
boolean
C0036341 (UMLS CUI [1])
C0036337 (UMLS CUI [2])
C0036337 (UMLS CUI [2])
Aggression and PANSS
Item
aggression: one episode of physical assault directed at another person in the hospital and persistence of violence/hostility for two weeks, as evidenced by the presence of some other physical, verbal or property assault or hostility, which would result in a score of 4 or more on the positive and negative syndrome scale (panss) hostility item.
boolean
C0001807 (UMLS CUI [1])
C0451383 (UMLS CUI [2])
C0451383 (UMLS CUI [2])
Hospitalization
Item
patients who were hospitalized for more than a year
boolean
C0019993 (UMLS CUI [1])
Nonresponse to clozapine, olanzapine or haloperidol
Item
patients who had a history of nonresponse to clozapine, olanzapine or haloperidol (defined as a lack of improvement despite a contiguous adequate trial of medication)
boolean
C3845351 (UMLS CUI [1,1])
C0009079 (UMLS CUI [1,2])
C3845351 (UMLS CUI [2,1])
C0171023 (UMLS CUI [2,2])
C3845351 (UMLS CUI [3,1])
C0018546 (UMLS CUI [3,2])
C0009079 (UMLS CUI [1,2])
C3845351 (UMLS CUI [2,1])
C0171023 (UMLS CUI [2,2])
C3845351 (UMLS CUI [3,1])
C0018546 (UMLS CUI [3,2])
Intolerance to clozapine, olanzapine, or haloperidol
Item
patients who had a history of clozapine, olanzapine, or haloperidol intolerance
boolean
C1744706 (UMLS CUI [1,1])
C0009079 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0171023 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C0018546 (UMLS CUI [3,2])
C0009079 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0171023 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C0018546 (UMLS CUI [3,2])
Comorbidity
Item
patients who had medical conditions that would be adversely affected by any of these three medications.
boolean
C0009488 (UMLS CUI [1])
Depot antipsychotic medication
Item
patients who received a depot antipsychotic within 30 days before randomization.
boolean
C2585377 (UMLS CUI [1])